Wealth Alliance
- SEC CIK
- 0001793904
- Latest filing
- Aug 11, 2026
NVS holding history
Novartis AG in every 13F filed by Wealth Alliance, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NVS overviewAll 13F holders of NVSFull Q2 2026 holdings
- Shares (Q2 2026)
- 3,181
- Value
- $498.5K
- % of portfolio
- <0.1%
- Quarters held
- 20
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,181 | $498.5K | <0.1% | −67−2.1% | Reduced | Holders |
| Q1 2026 | 3,248 | $496.1K | <0.1% | −314−8.8% | Reduced | Holders |
| Q4 2025 | 3,562 | $491.1K | <0.1% | −61−1.7% | Reduced | Holders |
| Q3 2025 | 3,623 | $464.6K | <0.1% | +56+1.6% | Added | Holders |
| Q2 2025 | 3,567 | $431.6K | <0.1% | −9−0.3% | Reduced | Holders |
| Q1 2025 | 3,576 | $398.6K | <0.1% | +149+4.3% | Added | Holders |
| Q4 2024 | 3,427 | $333.5K | <0.1% | −94−2.7% | Reduced | Holders |
| Q3 2024 | 3,521 | $405.0K | <0.1% | −162−4.4% | Reduced | Holders |
| Q2 2024 | 3,683 | $392.1K | 0.1% | +191+5.5% | Added | Holders |
| Q1 2024 | 3,492 | $337.7K | <0.1% | +72+2.1% | Added | Holders |
| Q4 2023 | 3,420 | $345.3K | <0.1% | −177−4.9% | Reduced | Holders |
| Q3 2023 | 3,597 | $366.4K | 0.1% | −392−9.8% | Reduced | Holders |
| Q2 2023 | 3,989 | $402.6K | 0.1% | −112−2.7% | Reduced | Holders |
| Q1 2023 | 4,101 | $377.3K | 0.1% | −17−0.4% | Reduced | Holders |
| Q4 2022 | 4,118 | $373.6K | 0.1% | −224−5.2% | Reduced | Holders |
| Q3 2022 | 4,342 | $330.0K | 0.1% | +921+26.9% | Added | Holders |
| Q2 2022 | 3,421 | $289.0K | 0.1% | +3,421 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −7,175−100.0% | Sold out | Holders |
| Q3 2021 | 7,175 | $586.0K | 0.1% | +253+3.7% | Added | Holders |
| Q2 2021 | 6,922 | $632.0K | 0.1% | +670+10.7% | Added | Holders |
| Q1 2021 | 6,252 | $534.0K | 0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.